CN101798298B - 咪唑衍生物 - Google Patents

咪唑衍生物 Download PDF

Info

Publication number
CN101798298B
CN101798298B CN2010101215002A CN201010121500A CN101798298B CN 101798298 B CN101798298 B CN 101798298B CN 2010101215002 A CN2010101215002 A CN 2010101215002A CN 201010121500 A CN201010121500 A CN 201010121500A CN 101798298 B CN101798298 B CN 101798298B
Authority
CN
China
Prior art keywords
methyl
phenyl
imidazol
methanol
imidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2010101215002A
Other languages
English (en)
Chinese (zh)
Other versions
CN101798298A (zh
Inventor
A·阿兰因
B·布特尔曼
M-P·海茨内德哈特
G·耶施克
E·皮纳德
R·维勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethiopia Wodtke International Co Ltd
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN101798298A publication Critical patent/CN101798298A/zh
Application granted granted Critical
Publication of CN101798298B publication Critical patent/CN101798298B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2010101215002A 2001-01-29 2002-01-21 咪唑衍生物 Expired - Fee Related CN101798298B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01101947 2001-01-29
EP01101947.8 2001-01-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN028042557A Division CN1489580B (zh) 2001-01-29 2002-01-21 咪唑衍生物

Publications (2)

Publication Number Publication Date
CN101798298A CN101798298A (zh) 2010-08-11
CN101798298B true CN101798298B (zh) 2013-01-09

Family

ID=8176317

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010101215002A Expired - Fee Related CN101798298B (zh) 2001-01-29 2002-01-21 咪唑衍生物
CN028042557A Expired - Fee Related CN1489580B (zh) 2001-01-29 2002-01-21 咪唑衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN028042557A Expired - Fee Related CN1489580B (zh) 2001-01-29 2002-01-21 咪唑衍生物

Country Status (23)

Country Link
US (3) US6610723B2 (enExample)
EP (1) EP1358165B1 (enExample)
JP (1) JP4094956B2 (enExample)
KR (1) KR100619106B1 (enExample)
CN (2) CN101798298B (enExample)
AR (1) AR035422A1 (enExample)
AT (1) ATE425147T1 (enExample)
BR (1) BR0206758A (enExample)
CA (1) CA2434813C (enExample)
CY (1) CY1110265T1 (enExample)
DE (1) DE60231477D1 (enExample)
DK (1) DK1358165T3 (enExample)
ES (1) ES2319967T3 (enExample)
GC (1) GC0000318A (enExample)
GT (1) GT200200013A (enExample)
JO (1) JO2292B1 (enExample)
MX (1) MXPA03006773A (enExample)
MY (1) MY138334A (enExample)
PA (1) PA8537801A1 (enExample)
PE (1) PE20020917A1 (enExample)
PT (1) PT1358165E (enExample)
WO (1) WO2002060877A1 (enExample)
ZA (1) ZA200305626B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030144B2 (en) * 2002-05-02 2006-04-18 Neurogen Corporation Substituted imidazole derivatives: GABAA receptor ligands
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
MXPA06014909A (es) * 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
ITRM20050094A1 (it) * 2005-03-04 2006-09-05 Univ Siena Derivati del 1-(1,5-di(4-clorofenil)-2metil-1h-3-pirroli)metil)-4-metilpiperazina (bm 212), procedimento per la loro produzione e uso di essi come antitubercolari.
US7939556B2 (en) 2005-10-14 2011-05-10 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
KR100694181B1 (ko) * 2005-11-25 2007-03-12 연세대학교 산학협력단 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법
RU2472788C9 (ru) * 2007-05-23 2013-04-20 Аллерган, Инк. (бициклогетероарил)имидазолил)метилгетероарильные соединения как агонисты адренергических рецепторов
WO2010009327A1 (en) * 2008-07-17 2010-01-21 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds for the treatment of pathologies associated with aging and degenerative disorders
BRPI0916576A2 (pt) 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
NZ601547A (en) 2010-01-25 2014-04-30 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2011101457A1 (en) 2010-02-18 2011-08-25 B.R.A.I.N. Biotechnology Research And Information Network Ag Chimeric surface active proteins
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤
SG2014012926A (en) 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013033068A1 (en) 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP6130383B2 (ja) 2011-09-30 2017-05-17 エンドゥ ファーマシューティカルズ,インコーポレイティド ピリジン誘導体
JP6105594B2 (ja) 2011-09-30 2017-03-29 エンドゥ ファーマシューティカルズ,インコーポレイティド 癌処置用cyp17阻害剤としてのイミダゾール誘導体
MX372995B (es) 2014-07-17 2020-04-13 Chdi Foundation Inc Metodos y composiciones para el tratamiento de trastornos relacionados con vih.
PT3180315T (pt) 2014-08-15 2020-05-27 Janssen Pharmaceuticals Inc Pirazoles
EP3180329B1 (en) * 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
KR20180108822A (ko) 2016-02-10 2018-10-04 얀센 파마슈티카 엔.브이. Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
EP3774732A4 (en) 2018-04-04 2022-02-09 Janssen Pharmaceutica NV PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
AU2020291188A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用
AU2020290772A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
EP3983413A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b
SG11202112407PA (en) 2019-06-14 2021-12-30 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
CN115656401B (zh) * 2022-11-09 2025-03-28 武汉海特生物创新医药研究有限公司 一种咪唑-4-甲酸乙酯纯度的hplc检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1088925A (zh) * 1993-01-02 1994-07-06 山道士有限公司 咪唑基甲基吡啶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3627155A1 (de) 1986-08-11 1988-02-18 Schering Ag Imidazol-derivate
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
IT1300055B1 (it) 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
ATE257827T1 (de) 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1088925A (zh) * 1993-01-02 1994-07-06 山道士有限公司 咪唑基甲基吡啶

Also Published As

Publication number Publication date
ATE425147T1 (de) 2009-03-15
ZA200305626B (en) 2004-10-21
MXPA03006773A (es) 2003-10-24
AR035422A1 (es) 2004-05-26
KR100619106B1 (ko) 2006-09-01
GT200200013A (es) 2002-09-02
DK1358165T3 (da) 2009-05-11
CA2434813C (en) 2009-12-22
JP4094956B2 (ja) 2008-06-04
MY138334A (en) 2009-05-29
WO2002060877A1 (en) 2002-08-08
US20030187268A1 (en) 2003-10-02
EP1358165B1 (en) 2009-03-11
ES2319967T3 (es) 2009-05-18
US20030191311A1 (en) 2003-10-09
PT1358165E (pt) 2009-04-22
CA2434813A1 (en) 2002-08-08
CN101798298A (zh) 2010-08-11
JP2004523535A (ja) 2004-08-05
EP1358165A1 (en) 2003-11-05
GC0000318A (en) 2006-11-01
PE20020917A1 (es) 2002-10-19
CN1489580B (zh) 2010-05-26
CN1489580A (zh) 2004-04-14
HK1063794A1 (en) 2005-01-14
DE60231477D1 (en) 2009-04-23
KR20030070615A (ko) 2003-08-30
US20020151715A1 (en) 2002-10-17
US6683097B2 (en) 2004-01-27
US6610723B2 (en) 2003-08-26
PA8537801A1 (es) 2002-09-17
US6667335B2 (en) 2003-12-23
JO2292B1 (en) 2005-09-12
HK1146646A1 (en) 2011-06-24
BR0206758A (pt) 2004-02-17
CY1110265T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
CN1489580B (zh) 咪唑衍生物
EP1194144B1 (en) Antibacterial compounds
US5332831A (en) Benzofuran derivatives
US5998437A (en) Benzimidazole derivatives
KR20000065227A (ko) 복소환 화합물, 그의 제조방법 및 용도
CA2129146A1 (en) Imidazole, triazole and tetrazole derivatives
CZ303101B6 (cs) Prípravek podporující tvorbu/sekreci neurotropinu
HK1245248B (en) Substituted heterocycles as bromodomain inhibitors
AU2009279137A1 (en) Pyrazolo [5,1-b] oxazole derivatives as CRF1 antagonists
US5922718A (en) Triazolones as apolipoprotein-B synthesis inhibitors
US20080214622A1 (en) Substituted Triazole Derivatives As Oxytocin Antagonists
US6248768B1 (en) Benzimidazole derivatives and pharmacologically acceptable salts thereof
JP2003277379A (ja) 含窒素複素環化合物、その製造法および用途
AU2002246043B2 (en) Imidazole derivatives
HK1146646B (en) Imidazole derivatives
HK1063794B (en) Imidazole derivatives
AU2002246043A1 (en) Imidazole derivatives
TWI328584B (en) Imidazole derivatives
AU2016366443A1 (en) Aminoazole derivative
ME01934B (me) Derivati pirazola kao modulatori protein kinaze
JP2969206B2 (ja) オキシトシン拮抗剤
JPWO2001030764A1 (ja) 1−置換フェニル−1−(1h−イミダゾール−4−イル)アルコール類、その製造法および用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1146646

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1146646

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: EVOTEC INTERNATIONAL GMBH

Free format text: FORMER OWNER: F. HOFFMANN-LA ROCHE AG

Effective date: 20130826

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130826

Address after: hamburg

Patentee after: Ethiopia wodtke International Co. Ltd.

Address before: Basel

Patentee before: F. Hoffmann-La Roche AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130109

Termination date: 20170121

CF01 Termination of patent right due to non-payment of annual fee